Projected Evolution of Anemia in Chronic Kidney Disease Market by 2032: Kind Pharmaceuticals, Genexine, Disc Medicine, and Others

To strategically aid Anemia in Chronic Kidney Disease companies developing drugs for Anemia in Chronic Kidney Disease, DelveInsight launched a report titled as “Anemia in Chronic Kidney Disease Market Insight Epidemiology and Market Forecast, 2032”. This comprehensive report delves into epidemiology based market analysis, providing a roadmap for success in the dynamic landscape of Anemia in Chronic Kidney Disease market.

Get a free sample of “Anemia in Chronic Kidney Disease Market Report”

Anemia in Chronic Kidney Disease Market Report’s Key Highlights:

• Anemia in Chronic Kidney Disease market is expected to grow during the study period in 7MM.
• Key Anemia in Chronic Kidney Disease Companies: Kind Pharmaceuticals, Genexine, Disc Medicine, Jiangsu HengRui Medicine, Shenyang Sunshine Pharmaceutical, Biocad, Xenetic Biosciences, Chiasma, Liminal BioSciences, Acceleron Pharma, Celgene Corporation, and others.
• According to the study conducted by Steven F. et al. (2018), in patients with stage 3 CKD, 22.2% of patients with diabetes were anemic, increasing to 52.4% in stage 4 CKD.
• According to NHANES survey, the prevalence of anemia increased with stage of CKD, from8.4% at stage 1to 53.4% at stage 5. A total of 22.8% of CKD patients with anemia reported being treated for anemia within the previous 3 months–14.6% of patients at CKD stages 1–2 and 26.4% of patients at stages 3–4.
• According to So fue et al. (2020), approximately 13% of the Japanese adult population is estimated to have CKD. The prevalence of anemia were 40.1% in patients with CKD stage G4 and 60.3% in patients with CKD stage G5.
• The Anemia in Chronic Kidney Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Anemia in Chronic Kidney Disease pipeline products will significantly revolutionize the Anemia in Chronic Kidney Disease market dynamics

Anemia in Chronic Kidney Disease Country based Treatment Analysis:?

The Anemia in Chronic Kidney Disease treatment market report provides treatment regimen across the 7MM. It will help companies to analyse the practices followed across 7MM, patient journey and advances in Anemia in Chronic Kidney Disease Therapies that have the potential to transform treatment paradigms and improve patient outcomes.

Anemia is a condition in which blood has a lower-than-normal amount of red blood.

Anemia is a common complication of chronic kidney disease (CKD). CKD means kidneys are damaged and cannot filter blood the way they should. This damage can cause wastes and fluid to build up in body.

Anemia is common in people with CKD, especially among people with more advanced kidney disease. More than37 million American adults may have CKD, and it is estimated that more than 1 out of every7people with kidney disease have anemia. Most people who have kidney failure, when kidney damage is so advanced that less than15 percent of the kidney is working normally, also have anemia.

People with CKD who also have diabetes are at greater risk for anemia, tend to develop anemia earlier, and often have more severe anemia than people with CKD who don't have diabetes. People older than 60 are also more likely to have anemia with CKD.

Anemia related to CKD typically develops slowly and may cause few or no symptoms in early kidney disease.

Symptoms of anemia in CKD may include, fatigue or tiredness, shortness of breath, unusually pale skin, weakness, body aches, chest pain, dizziness, fainting, fast or irregular heartbeat, headaches, sleep problems, and trouble concentrating.

Download the report to understand which factors are driving Anemia in Chronic Kidney Disease epidemiology trends @ Anemia in Chronic Kidney Disease Epidemiology Forecast

Anemia in Chronic Kidney Disease Epidemiology Insights:?

The report proffers historical and forecasted epidemiology insights that helps to understand the target patient population for Anemia in Chronic Kidney Disease. The analysis is from 2019-2032, providing insights how the patient trends are going to shape the market dynamics. Further, the epidemiology is segmented to provide in-depth analysis of patient pools allowing companies to understand their target patient’s pools. The epidemiology in report is segmented as:?

Anemia in Chronic Kidney Disease Epidemiology Segmentation:

• Total Prevalence of Anemia in Chronic Kidney Disease
• Prevalent Cases of Anemia in Chronic Kidney Disease by severity
• Gender-specific Prevalence of Anemia in Chronic Kidney Disease
• Diagnosed Cases of Episodic and Chronic Anemia in Chronic Kidney Disease

“Assessments as per DelveInsight’s analysts shows that no gender bias was reported in case of Anemia in chronic kidney disease”

Anemia in Chronic Kidney Disease Companies and Therapies:

• AND017: Kind Pharmaceuticals
• DISC-0974: Disc Medicine
• AND017: Kind Pharmaceuticals
• SSS17: Shenyang Sunshine Pharmaceutical
• BCD-066: Biocad

Emerging Anemia in Chronic Kidney Disease drugs Uptake:

• In February 2023, the US Food and Drug Administration approved JESDUVROQ tablets (daprodustat) as the first oral treatment for anemia (decreased number of red blood cells) caused by chronic kidney disease for adults who have been receiving dialysis for at least four months. However, in July2023, the company withdrew its application from the EMA.
• In April 2023, the European Commission approved VAFSEO (vadadustat) for the treatment of symptomatic anemia associated with CKD in adults on chronic maintenance dialysis.

To know more about Anemia in Chronic Kidney Disease companies working in the treatment market, visit @ Anemia in Chronic Kidney Disease Clinical Trials and Therapeutic Assessment

Anemia in Chronic Kidney Disease Market Forecast:

• The research includes a thorough analysis of the past and projected markets for Anemia in Chronic Kidney Disease, which includes pharmacological outreach in the 7MM nations.
• The dynamics of the Anemia in Chronic Kidney Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Bevacizumab, Axitinib, and others during the forecasted period 2019-2032.
• Rising prevalence, increasing prevalence, less competition for upcoming therapies and Companies shifting their focus to this area, despite low awareness of the disease are fuelling the Anemia in Chronic Kidney Disease Market.

Discover more about therapies set to grab major Anemia in Chronic Kidney Disease market share @ Anemia in Chronic Kidney Disease Treatment Market

Scope of the Anemia in Chronic Kidney Disease Market Report:?

• Geography Coverage: 7MM
• Study Period: 2019-2032
• Key Anemia in Chronic Kidney Disease Companies: Kind Pharmaceuticals, Genexine, Disc Medicine, Jiangsu HengRui Medicine, Shenyang Sunshine Pharmaceutical, Biocad, Xenetic Biosciences, Chiasma, Liminal BioSciences, Acceleron Pharma, Celgene Corporation, and others.

DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Anemia in Chronic Kidney Disease market landscape.

• Gain Competitive Edge in Indication Market: Understand the current landscape of the Anemia in Chronic Kidney Disease market, including the competitive environment, key companies developing drugs for Anemia in Chronic Kidney Disease, and their strategies. By analyzing Anemia in Chronic Kidney Disease market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.
• Identify Market Gaps and indication market opportunities: Analysing Anemia in Chronic Kidney Disease epidemiological trends, country wise patient journeys and existing treatment practices can helps in identifying gaps and opportunities within the Anemia in Chronic Kidney Disease market. This involves recognizing areas where current Anemia in Chronic Kidney Disease treatments may be insufficient or where there is an unmet need. The Anemia in Chronic Kidney Disease market report is curated by taking account of various KOLs dealing?with?Anemia in Chronic Kidney Disease. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific Anemia in Chronic Kidney Disease market needs and price their emerging products strategically to gain a competitive edge.
• Strategic decision making : Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing - reimbursement strategies, partnerships, or other strategic moves. Understanding the Anemia in Chronic Kidney Disease market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.
• Plan RoadMap to Success : Through this report the leading Anemia in Chronic Kidney Disease companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Anemia in Chronic Kidney Disease market with clarity and purpose.

Related Reports

Anemia in Chronic Kidney Disease Epidemiology Forecast

Anemia in Chronic Kidney Disease Epidemiology Forecast – 2032?report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and Anemia in Chronic Kidney Disease?epidemiology trends.

Anemia in Chronic Kidney Disease Pipeline

Anemia in Chronic Kidney Disease Pipeline Insight – 2023?report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key?Anemia in Chronic Kidney Disease companies, including?Kind Pharmaceuticals, Genexine, Disc Medicine, Jiangsu HengRui Medicine, Shenyang Sunshine Pharmaceutical, Biocad, Xenetic Biosciences, Chiasma, Liminal BioSciences, Acceleron Pharma, Celgene Corporation,?among others.

Explore Our Success Story on Building an Interactive Competitive Intelligence Dashboard for HR+ HER2- Breast Cancer Market Landscape. Download our Oncology Competitive Intelligence Case study!

About DelveInsight?

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact?

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Assistant Manager Marketing

Email: [email protected]

Website: https://www.delveinsight.com/consulting